Literature DB >> 10491815

Saturable transport of gabapentin at the blood-brain barrier.

M S Luer1, C Hamani, M Dujovny, B Gidal, M Cwik, K Deyo, J H Fischer.   

Abstract

Gabapentin readily crosses the blood-brain barrier and concentrates in brain tissue via an active transport process believed to be system-L. Blood-brain barrier system-L has a low K(m), making it particularly susceptible to substrate saturation. The purpose of this study was to determine whether the fraction of gabapentin crossing the blood-brain barrier remains constant over a broad range of doses. Using a rat model, microdialysis techniques were employed to determine if fluctuations in gabapentin concentrations in the brain extracellular fluid (ECF) coincided with proportional changes in plasma concentrations. Area under the concentration-time curve was calculated for plasma (AUCplasma) and brain extracellular fluid (AUCECF). The ratios of AUFECF to AUCplasma (AUCratio) and brain extracellular fluid to midpoint plasma gabapentin concentration for each collection interval (Cratio) were determined to provide indicators of the relative (i.e. fractional) amount of gabapentin crossing the blood-brain barrier. Analysis of the association between AUCECF and AUCplasma using linear regression analysis revealed a small, but significant relationship (r = 0.62; p < 0.01). Although higher AUCECF values were obtained with higher AUCplasma values, changes in AUCECF were less than proportional to observed changes in AUCplasma. Blood-brain barrier saturation of gabapentin transport was evident as the AUCratio decreased with increased AUCplasma. Collectively, these results support a trend towards saturation at higher plasma concentrations of the carrier-mediated transport mechanism of gabapentin through the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491815     DOI: 10.1080/01616412.1999.11740975

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  15 in total

Review 1.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

2.  PEPT1 enhances the uptake of gabapentin via trans-stimulation of b0,+ exchange.

Authors:  Theresa V Nguyen; David E Smith; David Fleisher
Journal:  Pharm Res       Date:  2006-12-28       Impact factor: 4.200

3.  71-year-old man with chronic kidney failure and sudden change of mental status.

Authors:  Aaron S Mansfield; Qi Qian
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

4.  In vivo and in vitro evaluations of intestinal gabapentin absorption: effect of dose and inhibitors on carrier-mediated transport.

Authors:  Malte Selch Larsen; Sidsel Frølund; Martha Kampp Nøhr; Carsten Uhd Nielsen; Mats Garmer; Mads Kreilgaard; René Holm
Journal:  Pharm Res       Date:  2014-09-03       Impact factor: 4.200

5.  Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model.

Authors:  Malte Selch Larsen; Ron Keizer; Gordon Munro; Arne Mørk; René Holm; Rada Savic; Mads Kreilgaard
Journal:  Pharm Res       Date:  2016-01-15       Impact factor: 4.200

Review 6.  Predictive validity of behavioural animal models for chronic pain.

Authors:  Odd-Geir Berge
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  In vivo effects of glycyl-glutamate and glycyl-sarcosine on gabapentin oral absorption in rat.

Authors:  Theresa V Nguyen; David Fleisher; David E Smith
Journal:  Pharm Res       Date:  2007-03-23       Impact factor: 4.200

Review 8.  Current developments in intraspinal agents for cancer and noncancer pain.

Authors:  Erin F Lawson; Mark S Wallace
Journal:  Curr Pain Headache Rep       Date:  2010-02

9.  Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin.

Authors:  B Brawek; M Löffler; D J Dooley; A Weyerbrock; T J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-12       Impact factor: 3.000

10.  Tri-partite complex for axonal transport drug delivery achieves pharmacological effect.

Authors:  Aaron G Filler; Garth T Whiteside; Mark Bacon; Martyn Frederickson; Franklyn A Howe; Miri D Rabinowitz; Alan J Sokoloff; Terrence W Deacon; Chris Abell; Raj Munglani; John R Griffiths; B Anthony Bell; Andrew M L Lever
Journal:  BMC Neurosci       Date:  2010-01-20       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.